Piece by piece, Amgen and AstraZeneca are building the case for their potential asthma blockbuster. The latest brick to fall into place comes from a new slice of phase 3 data, which suggests tezepelumab may be particularly effective in a subgroup of severe asthma patients.
The pre-specified exploratory analysis comes from a phase 3 clinical trial that linked tezepelumab to statistically significant reductions in exacerbations in asthma patients, including individuals with low counts of a white blood cell who have limited treatment options. The exploratory analysis points to the potential for tezepelumab to move the needle in another hard-to-treat subgroup of patients.
